Halbert Hargrove Global Advisors LLC Trims Holdings in Global X Genomics & Biotechnology ETF (NASDAQ:GNOM)

Halbert Hargrove Global Advisors LLC trimmed its position in Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) by 33.2% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,390 shares of the company’s stock after selling 4,169 shares during the quarter. Halbert Hargrove Global Advisors LLC owned about 0.12% of Global X Genomics & Biotechnology ETF worth $81,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in GNOM. Oxinas Partners Wealth Management LLC purchased a new stake in Global X Genomics & Biotechnology ETF in the 4th quarter worth approximately $103,000. Sanctuary Advisors LLC purchased a new stake in Global X Genomics & Biotechnology ETF in the 4th quarter worth approximately $104,000. Smartleaf Asset Management LLC increased its holdings in Global X Genomics & Biotechnology ETF by 11.2% in the 4th quarter. Smartleaf Asset Management LLC now owns 12,604 shares of the company’s stock worth $122,000 after acquiring an additional 1,265 shares in the last quarter. Atria Investments Inc purchased a new stake in Global X Genomics & Biotechnology ETF in the 3rd quarter worth approximately $122,000. Finally, Centaurus Financial Inc. increased its holdings in Global X Genomics & Biotechnology ETF by 7.0% in the 3rd quarter. Centaurus Financial Inc. now owns 14,996 shares of the company’s stock worth $169,000 after acquiring an additional 985 shares in the last quarter. 56.95% of the stock is owned by hedge funds and other institutional investors.

Global X Genomics & Biotechnology ETF Trading Up 0.8 %

NASDAQ:GNOM opened at $9.23 on Friday. Global X Genomics & Biotechnology ETF has a 12-month low of $9.04 and a 12-month high of $12.53. The stock has a 50-day moving average price of $9.88 and a 200 day moving average price of $10.49. The stock has a market capitalization of $64.33 million, a P/E ratio of -3.94 and a beta of 1.03.

About Global X Genomics & Biotechnology ETF

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research.